Literature DB >> 11799342

Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum ).

Andreas Johne1, Jürgen Schmider, Jürgen Brockmöller, Andreas M Stadelmann, Elke Störmer, Steffen Bauer, Gudrun Scholler, Matthias Langheinrich, Ivar Roots.   

Abstract

Extracts of St. John's wort ( Hypericum perforatum ) became increasingly popular as easily available remedies for mild to moderate depression. Comedication with hypericum extract was recently shown to drastically reduce plasma concentration of ciclosporin, digoxin, and indinavir. We investigated the possible interaction of hypericum extract LI160 with amitriptyline. Both antidepressants have a high probability of concomitant use. Twelve patients requiring amitriptyline treatment received a single dose of hypericum extract (900 mg) at day 1, continued by a 12-to 14-day treatment with retarded amitriptyline (75 mg twice daily). Then hypericum (900 mg/day) was added for another 14 to 16 days. Steady-state pharmacokinetics of amitriptyline were compared before and after multiple-dose treatment with hypericum extract. Furthermore, comparisons were made for single-dose kinetics of hypericum-extract ingredients hypericin, pseudohypericin, and hyperforin between the first day of concomitant treatment and LI160 alone. Multiple-dose comedication with LI160 led to a statistically significant decrease in the area under the plasma concentration-time curve within one dosing interval of amitriptyline by 22% ( p = 0.03) and nortriptyline by 41% ( p = 0.002), as well as of all hydroxylated metabolites, except for 10-E-hydroxynortriptyline. Plasma levels of amitriptyline and hydroxylated metabolites gradually decreased, whereas nortriptyline concentrations were already markedly decreased after 3 days of cotreatment with hypericum. Cumulative urinary amounts of amitriptyline and metabolites decreased to the same extent as plasma concentrations upon hypericum comedication. Induction of cytochrome P-450 enzymes or drug transporters (P-glycoprotein) by St. John's wort extract may explain this pharmacokinetic interaction. Physicians should be aware of this interaction when treating patients with amitriptyline.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799342     DOI: 10.1097/00004714-200202000-00008

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  31 in total

1.  Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients.

Authors:  Steffen Bauer; Elke Störmer; Andreas Johne; Hagen Krüger; Klemens Budde; Hans-Hellmut Neumayer; Ivar Roots; Ingrid Mai
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

2.  Drug-phytochemical interactions.

Authors:  Costas Ioannides
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 3.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

Review 4.  The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials.

Authors:  D L Whitten; S P Myers; J A Hawrelak; H Wohlmuth
Journal:  Br J Clin Pharmacol       Date:  2006-09-29       Impact factor: 4.335

Review 5.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

6.  Which medications used in paediatric practice have demonstrated natural health product-drug interactions?: Part A: Evidence-based answer and summary.

Authors:  Brad Johnston; Sunita Vohra
Journal:  Paediatr Child Health       Date:  2006-12       Impact factor: 2.253

Review 7.  Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood-Cerebrospinal Fluid Barrier and Blood-Brain Barrier.

Authors:  Lilian W Kibathi; SoHyun Bae; Scott R Penzak; Parag Kumar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

Review 8.  New developments in the pharmacodynamics and pharmacokinetics of combination of Chinese medicine and Western medicine.

Authors:  Di Liu; Xiao-Chun Liang
Journal:  Chin J Integr Med       Date:  2016-12-05       Impact factor: 1.978

9.  Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Xuemin Jiang; Kenneth M Williams; Winston S Liauw; Alaina J Ammit; Basil D Roufogalis; Colin C Duke; Richard O Day; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

10.  General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.

Authors:  Yoshiyuki Ohno; Akihiro Hisaka; Masaki Ueno; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.